United TherapeuticsCompany Review & Valuation

UTHR
Nasdaq
Latest Price
134.23USD
Market Capitalization
5.89bUSD

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacycShow morelin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. It has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.Show less

Industry
Biotechnology
HQ Location
Silver Spring, Maryland

Stock Price

Price data not available for United Therapeutics.

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Apricus Biosciences
NanoString Technologies
Biogen
Jazz Pharmaceuticals

back to top